SNSeonaid Nolan

Seonaid Nolan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Seonaid Nolan has a total of 112 co-authors. Here are the top co-authors by number of shared publications:

  • Rupinder Brar

    British Columbia Centre on Substance Use (BCCSU), Vancouver, Canada (RB, NF, SN); Department of Family Practice, University of British Columbia, Vancouver, Canada (RB, AR); Department of Medicine, University of British Columbia, St. Paul's Hospital, Vancouver, Canada (NF, SN); Department of Medicine, University of Calgary, Foothills Medical Centre – North Tower, NW Calgary, Canada (KC)

    5 shared publications
  • Christy Sutherland

    British Columbia Centre on Substance Use (BCCSU), Vancouver, BC, Canada (JW, NF, CS, CJ, SN), Department of Medicine, University of British Columbia, St. Paul's Hospital, Vancouver, BC, Canada (NF), Department of Family Practice, University of British Columbia, University Boulevard Vancouver, BC, Canada (CS), School of Nursing, University of British Columbia, Westbrook Mall, Vancouver, BC, Canada (CJ)

    4 shared publications
  • Evan Wood

    British Columbia Centre on Substance Use, 400-1045 Howe Street, Vancouver, V6Z 2A9 BC, Canada

    4 shared publications
  • Kanna Hayashi

    British Columbia Centre on Substance Use, Vancouver, Canada; Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada

    4 shared publications
  • Lianping Ti

    British Columbia Centre on Substance Use, Vancouver, Canada

    4 shared publications
  • Nadia Fairbairn

    British Columbia Centre on Substance Use Vancouver Canada

    4 shared publications

Latest Publications

  • A Descriptive Analysis of British Columbia’s Decriminalization Policy and its Impact on Access to Substances and Patterns of Use: Insights from the Road to Recovery Study

    by Elizabeth Carr, Rhea Beauchesne, Brittany Dennis, Travis De Wolfe, Harmony Johnson, Cheyenne Johnson, Seonaid Nolan

    Objectives: In January 2023, British Columbia (BC) received an exemption from federal legislation removing criminal penalties for possession of ≤ 2.5 g of unregulated drugs for personal use. This study aimed to identify perceived impacts of BC’s decriminalization policy on access to substances and patterns of use among patients accessing withdrawal management services. Methods: Data were collected through a cross-sectional survey of individuals enrolled in the Road to Recovery study [NCT06639373]. Participants who reported unregulated substance use (In this document, the term “unregulated substances” is used interchangeably with “previously designated criminalized substances,” which are defined as nonprescribed opioids, crack and/or powder cocaine, methamphetamines, and/or MDMA.) in the preceding 30 days were asked whether implementation of BC’s decriminalization policy impacted: (a) access to substances and/or (b) patterns of substance use. Results were summarized using descriptive statistics. Results: Among 91 eligible study participants, 50% identified as men, median age was 36 years (IQR: 18–73), 60% were white, and 88% had a lifetime history of unstable housing. Diagnosed substance use disorders included: 74% tobacco, 74% opioid, 57% stimulant, and 30% alcohol. Over half of participants (51%) felt implementation of BC’s decriminalization policy did not make it easier to access substances, compared with one-third (36%) who thought it did. Almost three-quarters (72%) believed the policy had no impact on their substance use patterns. Among 16% of participants who reported a change, 11% reported an increase, and 5% reported a decrease in substance use, respectively. Conclusions: Implementation of BC’s decriminalization policy had no perceived impact on patterns of substance use nor improved access to substances among the majority of study participants. Future research should examine association of the policy with health and social outcomes. Objectifs: En janvier 2023, la Colombie-Britannique (C.-B.) a obtenu une dérogation à la législation fédérale, supprimant ainsi les sanctions pénales pour la possession de moins de 2,5 grammes de drogues non réglementées à usage personnel. Cette étude visait à identifier les impacts perçus de la politique de décriminalisation de la C.-B. sur l’accès aux substances et les habitudes de consommation chez les patients bénéficiant de services de prise en charge du sevrage. Méthodes: Les données ont été recueillies au moyen d’une enquête transversale menée auprès de personnes participant à l’étude « Road to Recovery » [NCT06639373]. Les participants ayant déclaré avoir consommé des substances non réglementées au cours des 30 jours précédents ont été interrogés sur l’impact de la mise en œuvre de la politique de décriminalisation de la C.-B. sur : (a) l’accès aux substances ; et/ou (b) les habitudes de consommation. Les résultats ont été synthétisés à l’aide de statistiques descriptives. Résultats: Parmi les 91 participants éligibles à l’étude, 50% s’identifiaient comme des hommes, l’âge médian était de 36 ans (IQR : 18-73), 60% étaient de race blanche et 88% avaient des antécédents de situation de logement instable au cours de leur vie. Les troubles liés à la consommation de substances dont le diagnostic a été posé comprenaient : 74% pour le tabac, 74% pour les opiacés, 57% pour les stimulants et 30% pour l’alcool. Plus de la moitié des participants (51%) estimaient que la mise en œuvre de la politique de décriminalisation de la C.-B. n’avait pas facilité l’accès aux substances, contre un tiers (36%) qui pensaient le contraire. Près des trois quarts (72%) estimaient que cette politique n’avait eu aucun impact sur leurs habitudes de consommation. Parmi les 16% de participants ayant signalé un changement, 11% ont fait état d’une augmentation et 5% d’une diminution de leur consommation de substances, respectivement. Conclusions: La mise en œuvre de la politique de décriminalisation de la C.-B. n’a eu, selon la majorité des participants à l’étude, aucun impact perçu sur leurs habitudes de consommation de substances ni n’a amélioré l’accès à ces substances. De futures recherches devraient examiner le lien entre cette politique et les résultats en matière de santé et dans le domaine social.

  • Open Access

    Awareness, interest and use of a hospital-based overdose prevention site in Vancouver, Canada: a cross-sectional study

    by Cameron Proceviat, Jingxin Lei, Jeffrey Morgan, Piper Dickhout, Samantha Young, Lianping Ti, Seonaid Nolan

  • Open Access

    Safer supply deprescribing during a toxic drug poisoning crisis in Vancouver, Canada

    by Alexa Norton, Kanna Hayashi, Eric C. Sayre, Seonaid Nolan, Carol Strike, M.-J. Milloy, Thomas Kerr

  • Open Access

    Patient experiences and perceived efficacy of a newly implemented hospital-based withdrawal management unit in Vancouver, Canada: findings from the Road to Recovery evaluation

    by Sidney Roberge, Seonaid Nolan, Cheyenne Johnson, Piper Dickhout, Ava Abramowich, Travis De Wolfe, Renee Janssen, Erika Mundel, Andrea Ryan, Ian Haynes, et al.

    Background: The Road to Recovery (R2R) initiative represents an innovative approach to substance use care in British Columbia, Canada, that is designed to provide timely, comprehensive, and culturally safe services for individuals with a substance use disorder (SUD). This survey sought to understand patient experiences with this new care model. Methods: Adults (≥ 18 years) with a SUD who accessed R2R’s new hospital-based withdrawal management unit in Vancouver, Canada between May 2024 and April 2025 were invited to participate in a cross-sectional survey that captured their individual experiences. Descriptive statistics were used to summarize responses. Results: 87 participants completed the survey. The mean age was 41 years (Standard Deviation [SD] = 15); 57% ( n = 50) identified as male, and 49% ( n = 43) as Indigenous. The majority ( n = 58, 67%) of respondents reported access to withdrawal management services in ≤ 48 h. A total of 91% ( n = 79) of participants felt the quality of care was ‘good’ or ‘excellent’, 90% ( n = 78) reported positive interactions with staff, 88% ( n = 68) of respondents felt their withdrawal symptoms were adequately managed, 91% ( n = 71) believed the program helped them achieve their treatment goals. Among participants visited by Indigenous Wellness Liaisons (IWLs) (n = 56), 77% ( n = 43) completely trusted IWLs, and 52% ( n = 17) reported that their cultural and spiritual needs were completely met by IWLs. Peer support was valued by 85% of respondents for providing empathy and motivation. One-third ( n = 29, 33%) of participants contemplated leaving during their admission, most commonly because of the absence of engaging activities ( n = 12, 41%,). Overall, 95% said they would recommend the program to others. Conclusions: Findings highlight that the R2R model delivers timely, high-quality, and culturally safe withdrawal management care. Patients emphasized the value of respectful staff, effective medical management, and integration of Indigenous and peer supports. Enhancing structured programming and expanding access to psychosocial and cultural services may further improve engagement and reduce early discharge. Embedding trauma-informed, interdisciplinary, and culturally grounded approaches within hospital-based withdrawal management may improve patient experience and retention, informing future models of addiction care in Canada.

  • Open Access

    Capacity Building and Creating Supportive Environments for Inclusive Community-Based Participatory Research: A Case Study of the Overdose Prevention Peer Research Assistant (OPPRA) Project

    by Jeffrey Morgan, Tara Taylor, Seonaid Nolan, Alison Blais, Samuel Landon Cywink, Jean Mark Duguay, Thomas A. Gibbons, Scott Maxwell, Samona Marsh, Melanie Pratt, et al.

    Community members, service users, and people with lived experience, sometimes referred to as “peers,” are increasingly engaged in public health research and practice. The involvement of peers can enhance the acceptability and efficacy of public health interventions, foster trust, and is particularly significant in public health contexts characterized by stigma and criminalization. The involvement of peers in research, such as through community-based participatory research (CBPR) approaches, presents important opportunities for meaningful community engagement. However, the complex challenges associated with research training, capacity building and creating supportive research environments remain underexplored in the literature, particularly for communities that experience social exclusion and marginalization. This study presents a case study of the Overdose Prevention Peer Research Assistant (OPPRA) Project, a CBPR initiative that meaningfully involved harm reduction workers and people who use drugs in research about overdose prevention sites. We describe how inclusion and shared decision-making were accomplished through tailored research training and capacity building with peers and the process of developing supportive research environments that integrate social supports and meet peer research assistants “where they are at.” Further, we outline innovative and collaborative methods for data gathering and analysis developed to involve peers at every step of the research process and share the results of this original research. Results demonstrate the potential for overdose prevention sites to serve as critical points of connection and promote human rights and wellbeing for peer workers, service users, and the broader community.

  • Open Access

    Road to Recovery: protocol for a mixed-methods prospective cohort study evaluating the impact of a new model of substance use care in a Canadian setting

    by Brittany B Dennis, Jeanette Bowles, Cheyenne Johnson, Travis De Wolfe, Erika Mundel, Danya Fast, Jade Boyd, Mathew Fleury, Paxton Bach, Nadia Fairbairn, et al.

    Introduction The Road to Recovery (R2R) Initiative is an innovative model of substance use care that seeks to increase treatment capacity by creating approximately 100 new addiction treatment beds to provide on-demand addiction care in Vancouver, British Columbia, for patients with substance use disorders. The new model also coordinates the region’s existing clinical substance use services to support patients across a care continuum that includes traditional office-based addiction treatment and harm reduction services, early withdrawal management and more intensive abstinence-based treatment programming. To understand the impact of offering on-demand and coordinated substance use care, an observational cohort of individuals who access any R2R clinical service will be created to examine health and social outcomes over time. Methods and analysis This prospective mixed-methods study will invite individuals from Vancouver, Canada, who access substance use treatment through the R2R model of care to (1) complete a baseline and 12-month follow-up quantitative questionnaire that solicits sociodemographic, substance use and previous addiction treatment data and (2) provide consent to the use of participants’ personal identifiers to access health records for chart review and for annual linkage to select health and administrative databases to allow for ongoing (virtual) community follow-up over 5 years. Additionally, a purposive sample of cohort participants will be invited to participate in baseline and 12-month follow-up qualitative interviews to share their experiences accessing R2R and identify challenges and opportunities associated with the implementation of R2R. Ethics and dissemination The study was approved by the University of British Columbia Providence Health Care Research Ethics Board in September 2023. Results from the proposed study will be published in peer-reviewed journals, presented at national and international scientific conferences and disseminated through regular meetings with policymakers, individuals with lived and living experience, and other high-level stakeholders, academic presentations and lay media.


  • A Hospital-based Managed Alcohol Program in a Canadian Setting

    by Seonaid Nolan, Christopher Fairgrieve, Huiru Dong, Emma Msn Garrod, Holly Mha van Heukelom, Beena P. Parappilly, Mark McLean, Judith I. Tsui, Jeffrey H. Samet

    Objectives: A managed alcohol program (MAP) is a harm reduction strategy that provides regularly, witnessed alcohol to individuals with a severe alcohol use disorder. Although community MAPs have positive outcomes, applicability to hospital settings is unknown. This study describes a hospital-based MAP, characterizes its participants, and evaluates outcomes. Methods: A retrospective chart review of MAP participants was conducted at an academic hospital in Vancouver, Canada, between July 2016 and October 2017. Data included demographics, alcohol/substance use, alcohol withdrawal risk, and MAP indication. Outcomes after MAP initiation included the change in mean daily alcohol consumption and liver enzymes. Results: Seventeen patients participated in 26 hospital admissions: 76% male, mean age of 54 years, daily consumption prehospitalization of a mean 14 alcohol standard drinks, 59% reported previous nonbeverage alcohol consumption, and 41% participated in a community MAP. Most participants were high risk for severe, complicated alcohol withdrawal and presented in moderate withdrawal. Continuation of community MAP was the most common indication for hospital-based MAP initiation (38%), followed by a history of leaving hospital against medical advice (35%) and hospital illicit alcohol use (15%). Hospital-based MAP resulted in a mean of 5 fewer alcohol standard drinks daily compared with preadmission (P = 0.002; 95% confidence interval, 2–8) and improvement in liver enzymes, with few adverse events. Conclusions: Participation in a hospital-based MAP may be an effective safe approach to reduce harms for some individuals with severe alcohol use disorder. Further study is needed to understand who benefits most from hospital-MAP and potential benefits/harms following hospital discharge.


  • Harm reduction in the hospital: An overdose prevention site (OPS) at a Canadian hospital

    by Seonaid Nolan, Salpy Kelian, Thomas Kerr, Samantha Young, Isaac Malmgren, Cher Ghafari, Scott Harrison, Evan Wood, Mark Lysyshyn, Elizabeth Holliday


  • Supervised Tablet Injectable Opioid Agonist Therapy (TiOAT): A Strategy to Address Safer Supply for Individuals With an Opioid Use Disorder?

    by Jian Weng, Nadia Fairbairn, Christy Sutherland, Cheyenne Johnson, Seonaid Nolan

    North America is in the midst of an overdose crisis, with up to 130 Americans dying daily from a preventable drug overdose. Opioids account for 70% of overdose deaths. Despite government efforts to improve access to opioid use disorder (OUD) treatment and the implementation of various harm reduction initiatives, overdose mortality remains unacceptably high. Although effective treatments exist for OUD (eg, opioid agonist therapies like buprenorphine/naloxone and methadone), many individuals do not achieve stabilization with these medications. Tablet injectable opioid agonist therapy (TiOAT) is an initiative being piloted in British Columbia to provide witnessed access to a safer opioid supply for individuals with treatment-refractory OUD. The program offers participants a safer opioid supply through physician-prescribed pharmaceutical-grade hydromorphone tablets. TiOAT is suitable for individuals with severe OUD who are actively injecting opioids and are refractory to conventional OUD treatment. As such, a scale-up of the TiOAT program may be a feasible alternative to address persistent opioid-related deaths in North America, while minimizing potential harms associated with unwitnessed safer supply opioid prescribing (eg, diversion and overdose). Although a comprehensive evaluation of TiOAT is of critical importance (including an assessment of the program’s adverse events), completion of the evaluation should not preclude scale-up of the program in the interim as a strategy to reduce opioid-related harms.